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Abstract
Background: The association between obesity and the risk of Barrett's esophagus (BE) is unclear.
Furthermore, the association between visceral obesity and the risk of BE is entirely unknown.
Methods: We conducted a retrospective study in 163 patients with non-alcoholic fatty liver
disease (NAFLD) who underwent both endoscopy and abdominal CT at an interval of less than a
year at our institution. BE was endoscopically diagnosed based on the Prague C & M Criteria. The
surface areas of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were
calculated from CT images at the level of the umbilicus. The correlations between the BMI, VAT,
and SAT and the risk of BE were examined by univariate and multivariate analyses.
Results: Sixty-nine of the 163 study participants (42.3%) were diagnosed to have endoscopic BE,
which was classified as short-segment BE (SSBE) in almost all of the cases. There were no significant
differences in the age or gender distribution between the groups with and without BE. According
to the results of the univariate analysis, VAT was significantly associated with the risk of BE; the
BMI tended to be higher in the group with BE than in the group without BE, but this relation did
not reach statistical significance. VAT was independently associated with the risk of BE even after
adjustment for the BMI.
Conclusion: In Japanese patients with NAFLD, obesity tended to be associated with the risk of
BE, and this risk appeared to be mediated for the most part by abdominal visceral adiposity.
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Background
Metabolic syndrome is a cluster of metabolic abnormali-
ties consisting essentially of abdominal obesity, especially
visceral obesity, and has been highlighted as a risk factor
for the insulin resistance syndrome, cardiovascular dis-
ease, and other chronic diseases [1,2]. Non-alcoholic fatty
liver disease (NAFLD), a spectrum of liver disease ranging
from simple steatosis to non-alcoholic steatohepatitis, is
increasingly recognized as the hepatic manifestation of
metabolic syndrome, and liver inflammation and fibrosis
are directly associated with visceral obesity, independent
of insulin resistance and hepatic steatosis [3,4].
There has been a marked increase recently in the incidence
of gastroesophageal reflux disease (GERD)-related disor-
ders (symptoms, erosive esophagitis, Barrett's esophagus
(BE), and esophageal adenocarcinoma) in the United
States and western countries [5-7], and this has been par-
alleled by an increased prevalence of obesity [8,9]. Obes-
ity, as measured by the body mass index (BMI), is one of
the strongest risk factors for GERD symptoms, erosive
esophagitis, and esophageal adenocarcinoma [10-14],
while it remains controversial whether obesity is an inde-
pendent risk factor for BE. Several studies have examined
the association between obesity and BE and inconsistent
results have been reported, ranging from a significantly
increased risk associated with a high BMI [15,16], signifi-
cantly increased risk associated with a high BMI only in
the presence of GERD symptoms [17], or no association at
all [18]. There has been recent interest in the possible role
of abdominal obesity in the development of GERD-
related disorders. Recent studies have shown abdominal
obesity, as defined by the waist circumference (WC),
waist-to-hip ratio (WHR) or the surface area of the visceral
adipose tissue (VAT) as measured on abdominal com-
puted tomographic (CT) images, as a risk factor for BE
independent of the BMI, with the association between
BMI and BE being no longer observed after adjustment for
the WC, WHR, or VAT [15,19,20]. These studies suggest
that abdominal fat might mediate the association of obes-
ity with the risk of BE. In addition to the mechanical
effects of abdominal obesity, that is, increase of the intra-
abdominal pressure by the presence of a large amount of
adipose tissue, circulating factors secreted from the vis-
ceral adipose tissue, such as tumor necrosis factor-α(TNF-
α), interleukin-6 (IL-6), leptin, and adiponectin, have also
been proposed to be pathogenically linked to BE and
esophageal adenocarcinoma [21-26]. Although it is possi-
ble that visceral obesity, as the core of metabolic syn-
drome, may predict the risk of BE or esophageal
adenocarcinoma better than simple obesity, little evi-
dence exists confirming such associations. To the best of
our knowledge, no studies have been conducted until date
to examine the effect of visceral obesity, as measured on
abdominal CT images, on the risk of development of BE
in the Asian population.
In this retrospective study, we examined the effect of sim-
ple obesity, as measured by the BMI, and visceral obesity,
as measured on abdominal CT images, on the risk of BE
in Japanese patients with NAFLD, as the hepatic manifes-
tation of metabolic syndrome.
Methods
Patients
One hundred sixty-three consecutive NAFLD patients (83
men and 80 women; median age, 60 years; age range, 23–
80 years) who underwent both endoscopy and abdominal
CT at an interval of less than a year at the Gastroenterol-
ogy Division of Yokohama City University Hospital
between December 2003 and January 2009 were enrolled
in the present retrospective study. NAFLD was diagnosed
according to the following criteria: i) slight diffuse
increase in bright homogeneous echoes in the liver paren-
chyma with normal visualization of the diaphragm and
portal and hepatic vein borders and normal hepatorenal
echogenicity contrast; ii) diffuse increase in bright echoes
in the liver parenchyma with slightly impaired visualiza-
tion of the peripheral portal and hepatic vein borders; iii)
marked increase in bright echoes at a shallow depth with
deep attenuation, impaired visualization of the dia-
phragm and marked vascular blurring. The patients were
included if they fulfilled the following criteria: i) absence
of serological markers of hepatitis B virus infection (HBV
surface antigen and anti-HBc antibody) and hepatitis C
virus infection (anti-HCV antibody): ii) absence of evi-
dence of autoimmune liver disease or alcoholic liver dis-
ease (>20 g of alcohol per day).
The exclusion criteria were: difficulty in obtaining the
complete patient profiles from the medical records,
refusal of the patient to participate in the study, or a pre-
vious history of upper gastrointestinal tract surgery.
Endoscopic findings
Our hospital operates a digital filing system for endo-
scopic images. All the digital endoscopic images of the
enrolled subjects in this study were independently and
retrospectively reviewed by two trained endoscopists to
investigate the endoscopic findings, including hiatal her-
nia, erosive esophagitis, and BE. If there was any inconsist-
ency in the assessment of the digital endoscopic images
between the two investigators, the final diagnosis was
arrived at a joint review of the digital endoscopic images.
Hiatal hernia
Hiatal hernia was diagnosed when the distance between
the gastroesophageal junction and the diaphragmatic hia-
tus was 2 cm or more.BMC Gastroenterology 2009, 9:56 http://www.biomedcentral.com/1471-230X/9/56
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Erosive esophagitis
Erosive esophagitis was diagnosed based on the Los Ange-
les Classification [27] and was divided into three groups:
absent, mild (grades A and B), and severe (grades C and
D).
Barrett's esophagus
The presence of BE was diagnosed based on the Prague C
& M Criteria [28]. According to these criteria, BE is defined
as the macroscopic identification, using a standard endos-
copy exam, of abnormal columnar esophageal epithelium
suggestive of a columnar epithelium-lined distal esopha-
gus. The length of BE is measured (in centimeters) using
the circumferential extent (the C extent) and maximum
extent (the M extent) above the gastroesophageal junc-
tion, identified as the proximal margin of the gastric
mucosal folds [28].
Visceral adipose tissue (VAT) and Subcutaneous adipose 
tissue (SAT)
To quantify the visceral adipose tissue (VAT) and subcuta-
neous adipose tissue (SAT) area in cm2 using the Fat Scan
software (N2 System Corporation, Kobe, Japan), a simple
CT scan was obtained at the level of the umbilicus, with
an attenuation range of -50 to -250 Hounsfield units. VAT
was defined as intra-abdominal fat bound by parietal per-
itoneum or the fascia transversalis, excluding the vertebral
column and the paraspinal muscles, and SAT was defined
as fat superficial to the abdominal and back muscles.
Using a cursor, the VAT area was then measured around
the inner boundary of the abdominal wall muscles. A
region of interest (ROI) drawn around the external margin
of the dermis was used to calculate the total adipose tissue
(TAT) area. The SAT area was obtained by subtracting the
VAT area from the TAT area.
Patient profiles and Laboratory values
We collected information from the medical records on
demographic variables, BMI, serum leptin and adiponec-
tin levels, and other laboratory parameters, including
serum aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), cholinesterase (CHE), high-density
lipoprotein (HDL), low-density lipoprotein (LDL), trig-
lycerides (TG), and the HOMA-IR levels.
Ethics
The study was conducted in accordance with the Declara-
tion of Helsinki. The study protocol was approved by the
Ethics Committee of Yokohama City University Hospital.
All of the enrolled patients provided consent for participa-
tion in the study.
Statistical analysis
In the present study, the risk factors were compared
between patients with and without BE. The statistical
analysis included a Chi-square test or Fisher's exact test to
compare percentages and a Mann-Whitney U test to com-
pare continuous data. Various risk factors were also evalu-
ated simultaneously using a logistic regression model. The
statistical significance level was set at p < 0.05. All the sta-
tistical analyses were performed using the Stat View soft-
ware (SAS Institute, Cary, N.C.).
Results
The baseline characteristics of the study population are
summarized in Table 1. A total of 34 cases (20.9%) had
erosive esophagitis, which was mild (LA Classification
grades A and B) in most of the cases (17.8%), and severe
(LA Classification grades C and D) in only a few (3.1%)
(Table 1). The present study demonstrated that 42.3% of
the total study population was diagnosed as having BE
based on the Prague C & M Criteria [28]. These cases con-
sisted of 41.1% with short-segment BE (SSBE), whose cir-
cumferential (C) extent was less than 3 cm, and 1.2% with
long-segment BE (LSBE), whose C extent was 3 cm or
more (Table 1). Table 2 shows the results of a univariate
analysis conducted to compare the clinical characteristics
of the groups with and without BE. There were no signifi-
cant differences in the age (p = 0.8825) or gender distribu-
tion (p = 0.5542) between the two groups. As compared
to the group without BE, the group with BE showed higher
values of BMI, VAT, and SAT, although only the difference
in VAT reached statistical significance (p = 0.0089). The
prevalences of hiatal hernia (p < 0.0001) and erosive
esophagitis (p = 0.0099) were significantly higher in the
group with BE than in the group without BE (Table 2).
Multiple logistic regression analysis using clinical factors,
including the age, gender, BMI, hiatal hernia, VAT and
Table 1: Clinical characteristics of the patients enrolled in the 
present study.
Clinical characteristics Number (%)
Total number of patients 163
Patient profiles
Age: median; range (years) 60; 23–80
Sex: Female (%) 80 (49.1)
BMI: median; range 25.0; 19.2–43.6
Endoscopic results
Hiatal hernia (%) 41 (25.1)
Erosive esophagitis (%)
Total 34 (20.9)
Mild 29 (17.8)
Severe 5 (3.1)
Endoscopic BE (%)
Total 69 (42.3)
SSBE 67 (41.1)
LSBE 2 (1.2)
BMI; body mass index, BE; Barrett's esophagus, SSBE; short-segment 
Barrett's esophagus, LSBE; long-segment Barrett's esophagusBMC Gastroenterology 2009, 9:56 http://www.biomedcentral.com/1471-230X/9/56
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SAT was conducted to determine the clinical parameters
associated with BE (Table 3). Hiatal hernia (OR, 5.9343;
95% CI, 2.6515 – 13.2816) and VAT (OR, 1.0074; 95%
CI, 1.0001–1.0147) showed an independently significant
association with the risk of BE, while the BMI and SAT
showed no such association. In regard to the circulating
factors secreted from adipose tissue, while the serum adi-
ponectin level was significantly lower in the group with
BE than in the group without BE (p = 0.0089), the serum
leptin level tended to be higher in the group with BE than
in that without BE, although the difference did not reach
statistical significance (p = 0.5058) (Table 2). In other lab-
oratory parameters, the only serum CHE level was signifi-
cantly higher in the group with BE than in that without BE
(p = 0.0225). In addition, the serum AST (p = 0.0789) and
ALT (p = 0.0645) levels were higher in the group with BE
than in that without BE, but the differences did not reach
significant levels.
The study population frequently had suffered from hyper-
tension and taken Ca channel blockers, have the possibil-
ity of modification to LES pressure. But, no significant
difference of prevalence of taking Ca channel blocker
between BE group and non BE group (data not shown).
Discussion
In the present study, 42.3% (SSBE, 41.1%; LSBE, 1.2%) of
the study population was diagnosed as having BE based
on the Prague C & M Criteria (Table 1). The findings are
consistent with previous reports from Japan indicating
that SSBE is more common, while LSBE is rarer as com-
pared with the observations in the United States and
Table 2: Clinical characteristics of the patients according to the presence or absence of endoscopic Barrett's esophagus.
Endoscopic BE
Negative (n = 94) Positive (n = 69) P-value
Patients profiles
Age
median; range (years) 60; 23–80 60; 30–77 0.8825*
Sex
Female (%) 48 (51.1) 32 (46.4) 0.5542**
BMI
median; range 24.1; 19.2–39.7 25.8; 19.2–43.6 0.1354*
Endoscopic results
Hiatal hernia (%) 11 (11.7) 30 (43.5) <0.0001**
Erosive esophagitis (%) 13 (13.8) 21 (30.4) 0.0099**
Abdominal surface area
VAT (cm2) 97.45 (19.9–514.2) 120.2 (27.6–398.8) 0.0089*
SAT (cm2) 158.15 (34.5–428.7) 180.4 (35.2–484.8) 0.3169*
Circulating factors secreted from adipocytes
Leptin (ng/mL) 9.45 (2.5–27.6) 12.15 (2.7–26.4) 0.5058*
Adiponectin (μg/mL) 7.9 (3.2–21.4) 5.6 (3.2–12.5) 0.0089*
Other laboratory parameters
AST (U/L) 24 (12–112) 27 (12–204) 0.0789*
ALT (U/L) 30 (4–198) 32 (11–258) 0.0645*
CHE (U/L) 341 (208–719) 372 (198–545) 0.0225*
HDL (mg/dL) 57 (23–106) 50 (28–93) 0.1158*
LDL (mg/dL) 125.5 (40–202) 125 (61–241) 0.7548*
TG (mg/dL) 120 (50–524) 145 (52–809) 0.1076*
HOMA-R 2.444 (0.578–26.929) 3.184 (1.102–13.743) 0.3538*
*Mann-Whitney U test, **Chi square test.
Table 3: Multiple logistic regression analysis to identify the 
clinical factors associated with a risk of endoscopic Barrett's 
esophagus.
Factor Odds ratio 95% confidence interval P-value
Age 0.9990 0.9681–1.0308 0.9489
Sex: Female 1.1361 0.5063–2.5490 0.7569
BMI 0.9880 0.8640–1.1298 0.8597
Hiatal Hernia 5.9343 2.6515–13.2816 <0.0001
VAT 1.0074 1.0001–1.0147 0.0472
SAT 0.9990 0.9932–1.0048 0.7377BMC Gastroenterology 2009, 9:56 http://www.biomedcentral.com/1471-230X/9/56
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Western Europe [29,30]. The frequency of BE might be
affected by differences in its definition, in particular, by
whether the presence of intestinal metaplasia is essential
for making the diagnosis. The British Society of Gastroen-
terology guidelines propose that histological evidence of
specialized intestinal metaplasia is not necessary for the
diagnosis of BE, as its absence in one set of biopsies may
be solely due to sampling error, and the tissue might still
have an increased neoplastic potential as compared to
that lined by squamous epithelium [31]. This is consid-
ered as a realistic recognition. In other western countries,
the confirmation of the presence of intestinal metaplasia
of the esophagus by biopsy is essential for making a diag-
nosis of BE [32], as it is considered as a risk factor for
esophageal adenocarcinoma [33]. In this connection, in
the present study, BE was diagnosed endoscopically based
on the Prague C & M Criteria [28] without histological
confirmation, and was therefore defined as endoscopic
BE.
The results of univariate analysis in the present study con-
ducted on Japanese patients with NAFLD showed that
VAT was significantly associated with BE, whereas the
association of the BMI with BE did not reach statistical sig-
nificance (Table 2). Furthermore, the results of the multi-
variate analysis indicated that VAT was independently
associated with the risk of BE, even after adjustment for
the BMI and SAT (Table 3). El-Serag et al. reported, in a
case-control study in which the majority of the partici-
pants were white subjects, that both BMI and VAT were
significantly associated with an increased risk of BE, and
that VAT remained independently associated with the risk
of BE even after adjustment for BMI, while the significant
association between BMI and the risk of BE was abolished
after adjustment for VAT [15]. These findings suggest that
the effect of obesity on the risk of BE is mainly mediated
by abdominal obesity, especially the visceral fat area,
rather than by simple obesity. The difference in the
strength of association between BMI and the risk of BE
between these two reports might be explained, at least in
part, by ethnic differences in the obesity pattern, espe-
cially the pattern of visceral adipose deposition. Abdomi-
nal obesity can explain, in some part, the epidemiological
features of BE and esophageal adenocarcinoma. For exam-
ple, the body fat distribution tends towards visceral obes-
ity than simple obesity in high-risk groups for BE,
including Caucasians (as compared with Asian and Afri-
can populations), and men (as compared with women)
[34]. In addition, the increasing incidence of esophageal
adenocarcinoma over the past two decades has been par-
alleled by an increase in the prevalence of obesity [35].
Several plausible mechanisms might explain the relation
between abdominal obesity and the risk of BE and
esophageal adenocarcinoma [36,37]. First, abdominal
obesity can cause direct mechanical pressure on the stom-
ach, increasing the intragastric pressure and leading to a
higher frequency of relaxation of the lower esophageal
sphincter and consequent reflux. Recently, although both
BMI and WC have been reported to be associated with the
intragastric pressure and the gastroesophageal pressure
gradient, the WC has been reported to show a stronger
association than the BMI [38]. Accordingly, abdominal
obesity may be an important causative factor of GERD, as
a major risk factor for BE. A second mechanism may be
related to the metabolic activity of the adipose tissues,
especially the visceral adipose tissue, which release adi-
pokines, including IL-6 and TNF-α [21], that may play a
role in the development of BE or the consequent carcino-
genesis. Leptin is secreted predominantly by adipose tis-
sues, and the serum levels of this adipokine increase in
proportion to the body fat mass [22]. Leptin has been
shown to stimulate cell proferation and inhibit apoptosis
in Barrett's-derived EAC cells [23]. The characteristics of
increased proliferation and reduced apoptosis, which are
often noted in BE, are important for the progression to
cancer, because they promote the accumulation and per-
sistence of genetic abnormalities. Kendall BJ et al.
reported a threefold increased risk of BE among men with
serum leptin levels in the highest quartile, and that this
increase in the risk persisted even after adjustment for the
symptoms of GERD. In contrast, the risk of BE decreased
with increasing serum leptin levels in women [24]. In the
present study, the serum leptin levels tended to be higher
in the group with BE than in that without BE, however,
this relationship did not reach statistical significance
(Table 2). The study population in this study might have
been too small to allow examination of any gender differ-
ence in the association between the serum leptin and the
risk of BE (data not shown). Adiponectin is a peptide
secreted primarily from visceral adipocytes, and its serum
levels are inversely associated with the degree of obesity.
Adiponectin inhibits inflammation and promotes apop-
tosis, and deficiency of adiponectin has been implicated
in a number of epithelial cancers [25]. Rubenstein JH et al.
reported that deficiency of adiponectin was associated
with the presence of BE, even after adjustment for the
duration of GERD symptoms [26]. The present study
showed a significant association between the serum adi-
ponectin level and the risk of BE (Table 2), consistent with
the results of the aforesaid study. Analysis of other labora-
tory parameters indicated that NAFLD tend to be more
severe in the group with BE than in that without BE, the
relationship did not reach the significant level.
The present study results suggest that visceral obesity may
be involved in the risk of development of BE in Japanese
patients with NAFLD. As visceral obesity is the core com-
ponent of the metabolic syndrome, it may be considered
that the metabolic syndrome is associated with an ele-BMC Gastroenterology 2009, 9:56 http://www.biomedcentral.com/1471-230X/9/56
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vated risk of BE. Associations between BE and individual
components of the metabolic syndrome other than obes-
ity have not been clearly elucidated. Each component of
metabolic syndrome may interact to increase the risk of
BE; accordingly, a cluster of metabolic abnormalities that
fulfill the diagnostic criteria of metabolic syndrome may
increase the risk of BE to a greater degree than any individ-
ual metabolic abnormality. However, sufficient evidence
has not been collected to prove this hypothesis, and fur-
ther studies are needed to clarify these associations.
The present study rouse our interest in whether the same
association between visceral obesity and the risk of BE
may be drawn in patients with alcoholic liver disease
(ALD). But, the exact confirmation of the association is
thought to be difficult, because alcohol drinking habit is
also significantly associated with BE.
Our study also had several limitations that need to be con-
sidered. First, only NAFLD cases were included in our
study population. Whether our results would also be
applicable to the general population remains to be deter-
mined. There is no doubt NAFLD patients tend to have
more visceral obesity compared with the general popula-
tion. Second, our study population was probably too
small to allow examination of any gender differences in
the associations of obesity parameters with BE. Because
the prevalence of visceral obesity varies by gender [39],
gender differences possibly exist in the associations
between visceral obesity and circulating factors secreted
from adipocytes and the risk of BE.
A major advantage of this study was the use of CT, which
has a high degree of validity and reproducibility, to esti-
mate the abdominal fat area. Abdominal fat may be sub-
divided into SAT and VAT. While CT allows direct
assessment of these two fat compartments, anthropomet-
ric measurements (e.g., WC) do not [40]. The surface area
of VAT measured in a single-cut CT scan taken at the level
of the umbilicus has been shown to be a highly accurate
and reproducible measure of the volume of VAT (correla-
tion coefficient = 0.9) that may be calculated from 3-D
image reconstruction of multiple CT or MRI cuts [41,42].
VAT has been extensively used as an indicator of the
amount of abdominal fat, and has also been shown in
case-control and cohort studies to be a strong predictor of
the insulin resistance syndrome, diabetes, and coronary
artery disease. To the best of our knowledge, no studies
have been conducted until date to examine the effect of
visceral obesity, as measured by calculation of the surface
area of VAT, on the risk of development of BE in the Asian
population.
Conclusion
In summary, this study showed the existence of a signifi-
cant association between visceral obesity, as measured on
abdominal CT images, and the risk of BE in a Japanese
population with NAFLD. This raises several questions
regarding the pathogenesis of obesity-related GERD and
its potential complications, including BE. Larger studies
with prospective enrollment of patients are required for
further examination of this issue.
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